CD38 and Miyoshi myopathy: Moreover, in vitro experiments demonstrated that the use of the fully humanized anti-CD38 mAb, DARA, inhibits OC formation and activity, confirming the involvement of CD38 in bone remodeling, even in MM patients [31].